Fluoroquinolones in hospitalized patients with CAP: An evidence-based review

Infections in Medicine

Volumn 25, Issue 4, 2008, Pages 161-170

  Peyrani, Paula ^a   Ramirez, Julio A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Community acquired pneumonia; Fluoroquinolone therapy

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; ERYTHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; NONHUMAN; PATHOGENESIS; PSEUDOMONAS INFECTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 62249095120     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
2. Stanton MW. Improving Treatment Decisions for Patients With Community-Acquired Pneumonia. Research in Action Issue 7. Rockville, Md: Agency for Healthcare Research and Quality; 2002. AHRQ publication 02-0033.
3. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140-2145. (Pubitemid 38788182)
4. de Castro FR, Torres A. Optimizing treatment outcomes in severe community-acquired pneumonia. Am J Respir Med. 2003;2:39-54. (Pubitemid 37062716)
5. DeFrances CJ, Hall MJ. 2002 National Hospital Discharge Survey. Adv Data. 2004;342:1-29.
6. Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006;10(suppl 2):S1. (Pubitemid 351965558)
7. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250. (Pubitemid 27044625)
8. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-382. (Pubitemid 36560938)
9. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J. 2006;27:9-11. (Pubitemid 43092660)
10. Bodí M, Rodríguez A, Solé-Violán J, et al; Community-Acquired Pneumonia Intensive Care Unit (CAPICU) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact on adherence to Infectious Disease Society of America guidelines on survival. Clin Infect Dis. 2005;41:1709-1716.
11. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006;61:419-424.
12. Bauer TT, Ewig S, Marre R, et al; The CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260:93-101.
13. Leroy O, Vandenbussche C, Coffinier C, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med. 1997;156:1922-1929. (Pubitemid 28011803)
14. Levaquin [package insert]. Raritan, NJ: Ortho-McNeil; 2005.
15. Avelox [package insert]. Berlin: Bayer Pharmaceuticals Corporation; 2005.
16. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy. 2001;21(10 pt 2):233S-252S.
17. Zhanel GG, Roberts D, Waltky A, et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2002;49:807-812. (Pubitemid 34537642)
18. Jones RN, Fritsche TR, Sader HS. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2005;52:129-133.
19. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-750. (Pubitemid 34983995)
20. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy. 2002;22:395-399.
21. Endimiani A, Brigante G, Bettaccini AA, et al. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect Dis. 2005;5:106. (Pubitemid 41723747)
22. Empey PE, Jennings HR, Thornton AC, et al. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacolher. 2001;35:687-690.
23. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med. 2004;3:329-336. (Pubitemid 40045497)
24. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest. 2005;128:172-183. (Pubitemid 40994470)
25. Wasserfallen JB, Erard V, Cometta A, et al. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J. 2004;24:644-648. (Pubitemid 39406139)
26. Querol-Ribelles JM, Tenias JM, Querol-Borras JM, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents. 2005;25:75-83. (Pubitemid 40023350)
27. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760. (Pubitemid 37153652)
28. File TM Jr, Milkovich G, Tennenberg AM, et al. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin. 2004;20:1473-1481. (Pubitemid 39361352)
29. Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5-d and 10-d regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia. Clin Ther. 2005;27:1251-1259. (Pubitemid 41398096)
30. Anzueto A, Niederman MS, Pearle J, et al; Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006;42:73-81.
31. Morganroth J, Dimarco JP, Anzueto A, et al; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest. 2005;128:3398-3406.
32. Torres A, Read R, Lode H, et al. Once daily sequential intravenous/oral (IV/PO) moxifloxacin is equivalent to IV ceftriaxone plus twice daily IV/PO levofloxacin in the treatment of severe community-acquired pneumonia requiring hospitalization: the MOTIV study. Presented at: the 16th European Congress of Clinical Microbiology and Infectious Diseases [ECCMID]; April 1-4, 2006; Nice, France. Abstract 1061.
33. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002;46:1746-1754. (Pubitemid 34535192)
34. Welte T, Petermann W, Schurmann D, et al; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005;41:1697-1705.
35. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for non-severe community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis. 2005;24:367-376. (Pubitemid 40933911)
36. Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med. 2004;27:395-405. (Pubitemid 39388679)
37. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128:2238-2246. (Pubitemid 41507565)